top of page
Abstract Background

Gil is the Co-founder, Chairman and CEO of Armenta

Armenta, an AgTech company that is focused on developing non-antibiotic treatments for cattle diseases using acoustic technology.

Armenta has been granted EUR 2.3M under the Horizon 2020 program, in recognition of the company's groundbreaking work and its positive impact on sustainability, profitability, and animal welfare.

Gil is a seasoned executive with 20 years of experience in the Biotech and MedTech industry. He has a track record of success in developing and bringing new therapies and medical device products to market.

Prior to his current position, Gil was the CEO and then President of UroGen Pharma (NASDAQ: URGN). He led the company from its early/seed stages, defining its vision and strategy and developing new therapies in the treatment of urothelial cancer.

Before joining UroGen Pharma, Gil served as the Director of New Product Development at Medispec Ltd. There, he developed novel acoustic-based medical device products in fields such as cardiology, vascular medicine, urology, veterinary medicine, and dermatology.

Gil Hakim

Gil Hakim


bottom of page